ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic ...

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

A study reveals significant retinal vessel changes in diabetic retinopathy, highlighting the need for early detection methods ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell ...